Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  The nuclear speckles protein SRRM2 is a new therapeutic target molecule on the surface of cancer cells

Kellner, M., Hörmann, J., Fackler, S., Yuanyu, H., Tielin, Z., Lin, L., et al. (2024). The nuclear speckles protein SRRM2 is a new therapeutic target molecule on the surface of cancer cells. bioRxiv. doi:10.1101/2024.04.26.591288.

Item is

Dateien

einblenden: Dateien
ausblenden: Dateien
:
2024.04.26.591288v1.full.pdf (Preprint), 5MB
Name:
2024.04.26.591288v1.full.pdf
Beschreibung:
-
OA-Status:
Keine Angabe
Sichtbarkeit:
Öffentlich
MIME-Typ / Prüfsumme:
application/pdf / [MD5]
Technische Metadaten:
Copyright Datum:
-
Copyright Info:
© 2024, The Author(s)
Lizenz:
-

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Kellner, Markus , Autor
Hörmann, Julia , Autor
Fackler, Susanne , Autor
Yuanyu, Hu, Autor
Tielin, Zhou , Autor
Lin, Lu, Autor
Ilik, Ibrahim1, Autor                 
Aktas, Tugce1, Autor                 
Feederle, Regina , Autor
Hauck, Stefanie M. , Autor
Gires, Olivier , Autor
Gärtner, Kathrin , Autor
Lietao, Li, Autor
Zeidler, Reinhard , Autor
Affiliations:
1Quantitative RNA Biology (Tugce Aktas), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_3014184              

Inhalt

einblenden:
ausblenden:
Schlagwörter: -
 Zusammenfassung: The membrane composition of extracellular vesicles (EVs) largely reflects that of the plasma membrane of the cell of origin. We therefore hypothesized that EVs are a source for the detection of hitherto unknown tumor-associated druggable target molecules. For this, we used EVs derived from cancer cell lines for an immunization of a rat. From this immunization, we obtained a monoclonal antibody specific for SRRM2, a protein involved in splicing a major component of nuclear speckles. Here, we used this antibody to demonstrate that SRRM2 is exposed at the surface of most cancer cell lines from various entities and, even more important, on cancer cells in vivo. Moreover, we demonstrate that SRRM2-specific CAR-T cells are killing SRRM2-positive cancer cells electively. Collectively, we identified SRRM2 as a promising new target molecule exposed on the cancer cell surface and show that our SRRM2-specific antibody can be used as a basis for the development of new targeted cancer therapies.

Details

einblenden:
ausblenden:
Sprache(n):
 Datum: 2024-04-27
 Publikationsstatus: Online veröffentlicht
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: DOI: 10.1101/2024.04.26.591288
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: bioRxiv
Genre der Quelle: Webseite
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: -
Seiten: - Band / Heft: - Artikelnummer: - Start- / Endseite: - Identifikator: -